Purchased in 2007 by AstraZeneca for $15.6B, MedImmune has been researching and developing biopharmaceuticals since 1987. MedImmune will now perform its global biologics research and development for AstraZeneca working in the areas of oncology, respiratory, cardiovascular, renal and metabolic diseases, and infection and vaccines.
| Loading Documents... |
